Prostate Cancer - Results from #20

Preclinical Characterization of ARX517, a Site-specific Stable PSMA-Targeted Antibody Drug Conjugate for Treatment of Metastatic Castration-Resistant Prostate Cancer. November 13, 2024

A Randomized Controlled Trial of Gamification to Increase Physical Activity Among Black and Hispanic Breast and Prostate Cancer Survivors: Rationale and Design of the ALLSTAR Clinical Trial. November 12, 2024

Multi-task Bayesian model combining FDG-PET/CT imaging and clinical data for interpretable high-grade prostate cancer prognosis. November 12, 2024

Patients' anxieties and fears: a comparison between transrectal prostate biopsy and prostate MRI. November 12, 2024

Prostate cancer theragnostics biomarkers: An update. November 12, 2024

Prognostic role of prostate specific antigen kinetics in primary high volume metastatic hormonal sensitive prostate cancer treated with novel hormonal therapy agents. November 12, 2024

Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era November 11, 2024

Clarity and Nucleus RadioPharma Sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement November 11, 2024

Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer. November 11, 2024

Management of de novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and the role of Radiotherapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). November 11, 2024

Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare. November 11, 2024

Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. November 11, 2024

Advanced Imaging for Localized Prostate Cancer. November 11, 2024

Long-Term Adverse Effects and Complications After Prostate Cancer Treatment November 8, 2024

5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer. November 8, 2024

The inhibition effect of psoralen on prostate cancer PC3 cells via down-regulation of long non-coding RNA ENST00000510619. November 8, 2024

Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer. November 8, 2024

Value of Whole-body Magnetic Resonance Imaging Using the MET-RADS-P Criteria for Assessing the Response to Intensified Androgen Deprivation Therapy in Metastatic Hormone-naïve and Castration-resistant Prostate Cancer. November 8, 2024

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer. November 8, 2024

The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial. November 8, 2024

Page 2 of 1438